178 related articles for article (PubMed ID: 35185898)
1. Association of Peripheral Blood Biomarkers With Response to Anti-PD-1 Immunotherapy for Patients With Deficient Mismatch Repair Metastatic Colorectal Cancer: A Multicenter Cohort Study.
Cheng YK; Chen DW; Chen P; He X; Li PS; Lin ZS; Chen SX; Ye SB; Lan P
Front Immunol; 2022; 13():809971. PubMed ID: 35185898
[TBL] [Abstract][Full Text] [Related]
2. Dickkopf 1 impairs the tumor response to PD-1 blockade by inactivating CD8+ T cells in deficient mismatch repair colorectal cancer.
Sui Q; Liu D; Jiang W; Tang J; Kong L; Han K; Liao L; Li Y; Ou Q; Xiao B; Liu G; Ling Y; Chen J; Liu Z; Zuo Z; Pan Z; Zhou P; Zheng J; Ding PR
J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33782107
[TBL] [Abstract][Full Text] [Related]
3. Tumour mutational burden as a biomarker in patients with mismatch repair deficient/microsatellite instability-high metastatic colorectal cancer treated with immune checkpoint inhibitors.
Manca P; Corti F; Intini R; Mazzoli G; Miceli R; Germani MM; Bergamo F; Ambrosini M; Cristarella E; Cerantola R; Boccaccio C; Ricagno G; Ghelardi F; Randon G; Leoncini G; Milione M; Fassan M; Cremolini C; Lonardi S; Pietrantonio F
Eur J Cancer; 2023 Jul; 187():15-24. PubMed ID: 37099945
[TBL] [Abstract][Full Text] [Related]
4. Prediction of Benefit from Checkpoint Inhibitors in Mismatch Repair Deficient Metastatic Colorectal Cancer: Role of Tumor Infiltrating Lymphocytes.
Loupakis F; Depetris I; Biason P; Intini R; Prete AA; Leone F; Lombardi P; Filippi R; Spallanzani A; Cascinu S; Bonetti LR; Maddalena G; Valeri N; Sottoriva A; Zapata L; Salmaso R; Munari G; Rugge M; Dei Tos AP; Golovato J; Sanborn JZ; Nguyen A; Schirripa M; Zagonel V; Lonardi S; Fassan M
Oncologist; 2020 Jun; 25(6):481-487. PubMed ID: 31967692
[TBL] [Abstract][Full Text] [Related]
5. Comparative Effectiveness of Immune Checkpoint Inhibitors vs Chemotherapy in Patients With Metastatic Colorectal Cancer With Measures of Microsatellite Instability, Mismatch Repair, or Tumor Mutational Burden.
Quintanilha JCF; Graf RP; Fisher VA; Oxnard GR; Ellis H; Panarelli N; Lin DI; Li G; Huang RSP; Ross JS; Myer PA; Klempner SJ
JAMA Netw Open; 2023 Jan; 6(1):e2252244. PubMed ID: 36689222
[TBL] [Abstract][Full Text] [Related]
6. Biomarkers of Pathologic Complete Response to Neoadjuvant Immunotherapy in Mismatch Repair-Deficient Colorectal Cancer.
Li J; Hu H; Qin G; Bai F; Wu X; Ke H; Zhang J; Xie Y; Wu Z; Fu Y; Zheng H; Gong L; Xie Z; Deng Y
Clin Cancer Res; 2024 Jan; 30(2):368-378. PubMed ID: 37906636
[TBL] [Abstract][Full Text] [Related]
7. Association Between Survival and Metastatic Site in Mismatch Repair-Deficient Metastatic Colorectal Cancer Treated With First-line Pembrolizumab.
Saberzadeh-Ardestani B; Jones JC; Hubbard JM; McWilliams RR; Halfdanarson TR; Shi Q; Sonbol MB; Ticku J; Jin Z; Sinicrope FA
JAMA Netw Open; 2023 Feb; 6(2):e230400. PubMed ID: 36811859
[TBL] [Abstract][Full Text] [Related]
8. Discordant prognosis of mismatch repair deficiency in colorectal and endometrial cancer reflects variation in antitumour immune response and immune escape.
Glaire MA; Ryan NA; Ijsselsteijn ME; Kedzierska K; Obolenski S; Ali R; Crosbie EJ; Bosse T; de Miranda NF; Church DN
J Pathol; 2022 Jul; 257(3):340-351. PubMed ID: 35262923
[TBL] [Abstract][Full Text] [Related]
9. Immunotherapy in mismatch repair-deficient metastatic colorectal cancer - Outcome and novel predictive markers.
Stemmer A; Margalit O; Serpas V; Strauss G; Thomas J; Shah P; Tau N; Levanon K; Shacham-Shmueli E; Kopetz S; Overman M; Boursi B
Eur J Cancer; 2024 Feb; 198():113495. PubMed ID: 38157568
[TBL] [Abstract][Full Text] [Related]
10. Antibiotic Exposure Does Not Impact Immune Checkpoint Blockade Response in MSI-H/dMMR Metastatic Colorectal Cancer: A Single-Center Experience.
Serpas Higbie V; Rogers J; Hwang H; Qiao W; Xiao L; Dasari A; Mola-Rudd K; Morris VK; Wolff RA; Raghav K; Huey R; Parseghian C; Willis J; Kopetz S; Overman MJ; Johnson B
Oncologist; 2022 Nov; 27(11):952-957. PubMed ID: 35946836
[TBL] [Abstract][Full Text] [Related]
11. Immune Marker Spatial Distribution and Clinical Outcome after PD-1 Blockade in Mismatch Repair-deficient, Advanced Colorectal Carcinomas.
Saberzadeh-Ardestani B; Graham RP; McMahon S; Ahanonu E; Shi Q; Williams C; Hubbard A; Zhang W; Muranyi A; Yan D; Jin Z; Shanmugam K; Sinicrope FA
Clin Cancer Res; 2023 Oct; 29(20):4268-4277. PubMed ID: 37566222
[TBL] [Abstract][Full Text] [Related]
12. Circulating memory PD-1
Liu J; Liu D; Hu G; Wang J; Chen D; Song C; Cai Y; Zhai C; Xu W
Cancer Cell Int; 2023 Nov; 23(1):274. PubMed ID: 37974194
[TBL] [Abstract][Full Text] [Related]
13. Clinicopathological characteristics, molecular landscape, and biomarker landscape for predicting the efficacy of PD-1/PD-L1 inhibitors in Chinese population with mismatch repair deficient urothelial carcinoma: a real-world study.
Ma YT; Hua F; Zhong XM; Xue YJ; Li J; Nie YC; Zhang XD; Ma JW; Lin CH; Zhang HZ; He W; Sha D; Zhao MQ; Yao ZG
Front Immunol; 2023; 14():1269097. PubMed ID: 38022513
[TBL] [Abstract][Full Text] [Related]
14. Immune checkpoint inhibitors for POLE or POLD1 proofreading-deficient metastatic colorectal cancer.
Ambrosini M; Rousseau B; Manca P; Artz O; Marabelle A; André T; Maddalena G; Mazzoli G; Intini R; Cohen R; Cercek A; Segal NH; Saltz L; Varghese AM; Yaeger R; Nusrat M; Goldberg Z; Ku GY; El Dika I; Margalit O; Grinshpun A; Kasi P; Schilsky R; Lutfi A; Shacham-Shmueli E; Khan Afghan M; Weiss L; Westphalen CB; Conca V; Decker B; Randon G; Elez E; Fakih M; Schrock AB; Cremolini C; Jayachandran P; Overman MJ; Lonardi S; Pietrantonio F
Ann Oncol; 2024 May; ():. PubMed ID: 38777726
[TBL] [Abstract][Full Text] [Related]
15. Peripheral CD4
Yang X; Li Q; Zeng T
Front Immunol; 2024; 15():1364507. PubMed ID: 38650951
[TBL] [Abstract][Full Text] [Related]
16. Metastatic site and clinical outcome of patients with deficient mismatch repair metastatic colorectal cancer treated with an immune checkpoint inhibitor in the first-line setting.
Saberzadeh-Ardestani B; Jones JC; McWilliams RR; Tougeron D; Halfdanarson TR; Guimbaud R; Hubbard JM; Flecchia C; Shi Q; Alouani E; Sonbol MB; Ticku J; Jin Z; Taieb J; Sinicrope FA
Eur J Cancer; 2024 Jan; 196():113433. PubMed ID: 37979306
[TBL] [Abstract][Full Text] [Related]
17. PD-1 blockade plus COX inhibitors in dMMR metastatic colorectal cancer: Clinical, genomic, and immunologic analyses from the PCOX trial.
Wu Z; Zhang Y; Cheng Y; Li J; Li F; Wang C; Shi L; Qin G; Zhan W; Cai Y; Xie X; Ling J; Hu H; Zhang J; Deng Y
Med; 2024 May; ():. PubMed ID: 38795703
[TBL] [Abstract][Full Text] [Related]
18. Expanding the Scope of Immunotherapy in Colorectal Cancer: Current Clinical Approaches and Future Directions.
Kreidieh M; Mukherji D; Temraz S; Shamseddine A
Biomed Res Int; 2020; 2020():9037217. PubMed ID: 32090113
[TBL] [Abstract][Full Text] [Related]
19. Phase II Trial of Nivolumab in Metastatic Rare Cancer with dMMR or MSI-H and Relation with Immune Phenotypic Analysis (the ROCK Trial).
Okuma HS; Watanabe K; Tsuchihashi K; Machida R; Sadachi R; Hirakawa A; Ariyama H; Kanai M; Kamikura M; Anjo K; Hiramitsu A; Sekine S; Okita N; Mano H; Nishikawa H; Nakamura K; Yonemori K
Clin Cancer Res; 2023 Dec; 29(24):5079-5086. PubMed ID: 37819940
[TBL] [Abstract][Full Text] [Related]
20. Nomogram to predict the outcomes of patients with microsatellite instability-high metastatic colorectal cancer receiving immune checkpoint inhibitors.
Pietrantonio F; Lonardi S; Corti F; Infante G; Elez ME; Fakih M; Jayachandran P; Shah AT; Salati M; Fenocchio E; Salvatore L; Curigliano G; Cremolini C; Ambrosini M; Ros J; Intini R; Nappo F; Damian S; Morano F; Fucà G; Overman M; Miceli R
J Immunother Cancer; 2021 Aug; 9(8):. PubMed ID: 34429334
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
